Increased competition among biotech VCs in China.
Shift from waiting for assets to proactively investing.
Focus on upstream scientific pipelines.
Briefing: Biotech VCs Move Upstream in China's Scientific Pipelines
Strategic angle: U.S. venture capital firms are proactively investing in Chinese biotech, shifting their strategy as competition intensifies.